Cargando…

Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database

Several systems (tumor‐node‐metastasis [TNM], Barcelona Clinic Liver Cancer [BCLC], Okuda, Cancer of the Liver Italian Program [CLIP], and albumin–bilirubin grade [ALBI]) were developed to estimate the prognosis of patients with hepatocellular carcinoma (HCC) mostly prior to the prevalent use of sor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samawi, Haider H., Sim, Hao‐Wen, Chan, Kelvin K., Alghamdi, Mohammad A., Lee‐Ying, Richard M., Knox, Jennifer J., Gill, Parneet, Romagnino, Adriana, Batuyong, Eugene, Ko, Yoo‐Joung, Davies, Janine M., Lim, Howard J., Cheung, Winson Y., Tam, Vincent C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051235/ https://www.ncbi.nlm.nih.gov/pubmed/29766659 http://dx.doi.org/10.1002/cam4.1493

Ejemplares similares

Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database
por: Alghamdi, Mohammed A., et al.
Publicado: (2020)

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab
por: Fung, Andrea S., et al.
Publicado: (2020)

Effectiveness and components of self-management interventions in adult cancer survivors: a protocol for a systematic review and planned meta-analysis
por: Cuthbert, Colleen Ann, et al.
Publicado: (2018)

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
por: El Dika, Imane, et al.
Publicado: (2020)

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
por: Groenendijk, Floris H, et al.
Publicado: (2015)

Comprehensive analysis of long noncoding RNA and mRNA in five colorectal cancer tissues and five normal tissues
por: Zhou, Zhen-Xu, et al.
Publicado: (2020)

FAM225A promotes sorafenib resistance in hepatocarcinoma cells through modulating miR-130a-5p–CCNG1 interaction network
por: Liu, Yan-Tong, et al.
Publicado: (2020)

A real‐world, population‐based study of patterns of referral, treatment, and outcomes for advanced pancreatic cancer
por: Abdel‐Rahman, Omar, et al.
Publicado: (2018)

Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
por: Labeur, Tim A., et al.
Publicado: (2019)

Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies
por: Reed, Damon R., et al.
Publicado: (2015)

Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma
por: Dai, Jimin, et al.
Publicado: (2018)

Discussions about reproductive and sexual health among young adult survivors of cancer
por: Wang, Ying, et al.
Publicado: (2016)

Compliance with adjuvant capecitabine in patients with stage II and III colon cancer: comparison of administrative versus medical record data
por: Amlani, Adam, et al.
Publicado: (2016)

Five-year single-centre experience of carcinoma of the oesophagus from Blantyre, Malawi
por: Chetwood, John David, et al.
Publicado: (2018)

Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases
por: Okada, Keiko, et al.
Publicado: (2016)

Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma
por: Liang, Yuelong, et al.
Publicado: (2017)

The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group
por: Chan, Kelvin K. W., et al.
Publicado: (2021)

Occupational exposure to magnetic fields and breast cancer among Canadian men
por: Grundy, Anne, et al.
Publicado: (2016)

Cost‐effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person‐level data in a Canadian setting
por: Thein, Hla‐Hla, et al.
Publicado: (2017)

Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer
por: Liu, Bo, et al.
Publicado: (2021)

Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison
por: De Oliveira, Claire, et al.
Publicado: (2017)

Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non–Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2
por: Finn, Richard S, et al.
Publicado: (2022)

PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma
por: Wang, Pusen, et al.
Publicado: (2020)

Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study
por: Nakano, Masahito, et al.
Publicado: (2015)

Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma
por: Ito, Yasuhiro, et al.
Publicado: (2017)

Bladder cancer and occupational exposure to diesel and gasoline engine emissions among Canadian men
por: Latifovic, Lidija, et al.
Publicado: (2015)

Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap
por: McCuaig, Jeanna M, et al.
Publicado: (2018)

Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial
por: Salem, Riad, et al.
Publicado: (2021)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
por: Hsu, Po‐Yao, et al.
Publicado: (2021)

Prostate cancer surveillance by occupation and industry: the Canadian Census Health and Environment Cohort (CanCHEC)
por: Sritharan, Jeavana, et al.
Publicado: (2018)

Universal tumor screening for Lynch syndrome: Perceptions of Canadian pathologists and genetic counselors of barriers and facilitators
por: Dicks, Elizabeth, et al.
Publicado: (2019)

Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized study
por: Haruna, Yoshimichi, et al.
Publicado: (2021)

Long‐term risk of cardiovascular mortality in lymphoma survivors: A systematic review and meta‐analysis
por: Boyne, Devon J., et al.
Publicado: (2018)

SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR‐23b‐3p via sponging EGR1 in hepatocellular carcinoma
por: Jing, Zhao, et al.
Publicado: (2020)

Life dissatisfaction in Canadians aged 40 and above with cancer and mental health disorders: A cross‐sectional study using the Canadian Community Health Survey
por: Roy, Danielle Carole, et al.
Publicado: (2021)

Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute
por: Hainsworth, John D, et al.
Publicado: (2015)

Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario
por: McGee, Jacob, et al.
Publicado: (2017)

Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib
por: Niinivirta, Marjut, et al.
Publicado: (2017)

Hydrogen Bonds, Topologies, Energy Frameworks and Solubilities of Five Sorafenib Salts
por: Phan, Chiuyen, et al.
Publicado: (2021)

Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients
por: Belch, Andrew, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nood52584bj4v6o3jspiocal9b